is manjaro a glp 1 GLP-1 Weight Loss Treatments: Ozempic, Mounjaro, and Other Options| PMN Mounjaro (Tirzepatide): Raising the Bar

USA 115 , E10988E10997 (2018)

The FDAs Cardiovascular and Renal Drugs Advisory Committee voted 9-3 that patisirans benefits outweigh its risks in this indication, despite concerns expressed in FDA briefing documents prior to the adcomm meeting

Individuals who are prescribed Wegovy generally must meet the following criteria: Adults with BMI 30 (obesity) Adults with BMI 27 (overweight) with a weight-related health condition Children 12 years and older with a BMI in the 95th percentile or higher (obesity) Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist

The molecule is identical across both products the differences are dosing schedule and approved indication, not chemistry